Leibovich评分在局限性肾细胞癌中的英国多中心前瞻性评估:性能随时间变化
在当代局限性透明细胞RCC队列中,Leibovich评分模型区分度良好(c-index=0.77)但校准欠佳,中危和高危患者5年MFS分别为85%和50%,高于原始Leibovich队列(74%和31%)及英国历史队列(76%和37%);模型解释的结局变异比例较低且随时间下降(历史队列28% vs 当代英国队列22%)。
要点
- 当代局限性透明细胞RCC中Leibovich评分区分度良好(c-index=0.77),但校准欠佳。
- 中危和高危患者5年MFS分别为85%和50%,高于原始及历史队列。
- 模型解释的结局变异比例低且随时间下降(28%→22%),多数变异未解释。
核心结论
- Leibovich模型在当代英国局限性透明细胞RCC队列中区分度良好但校准欠佳,中危和高危患者MFS较历史队列改善。
- 模型解释的结局变异比例低且随时间下降,多数结局变异仍未解释,可能影响所有同类预后模型的应用。
研究设计与样本
- 另设历史队列(1998-2006)用于比较。
主要发现
- 当代队列中Leibovich评分对局限性透明细胞RCC的区分度c-index=0.77。
- 中危患者5年MFS为85%,高危为50%;原始Leibovich队列分别为74%和31%,英国历史队列分别为76%和37%。
- 模型解释的结局变异比例历史队列为28%,当代英国队列为22%。
临床怎么用
- Leibovich评分可用于局限性RCC的预后分层,但需注意当代患者MFS已改善且模型校准欠佳。
- 在指导随访强度和临床试验筛选时,应结合模型区分度与校准随时间的变化。
局限性
- 原文未明确报告模型校准的具体指标。
- 历史队列与当代队列的对比可能受时间偏倚影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine changes in outcome by the Leibovich score using contemporary and historic cohorts of patients presenting with renal cell carcinoma (RCC) PATIENTS AND METHODS: Prospective observational multicenter cohort study, recruiting patients with suspected newly diagnosed RCC. A historical cohort of patients was examined for comparison. Metastasis-free survival (MFS) formed the primary outcome measure. Model discrimination and calibration were evaluated using Cox proportional hazard regression and the Kaplan-Meier method. Overall performance of the Leibovich model was assessed by estimating explained variation. RESULTS: Seven hundred and six patients were recruited between 2011 and 2014 and RCC confirmed in 608 (86%) patients. Application of the Leibovich score to patients with localized clear cell RCC in this contemporary cohort demonstrated good model discrimination (c-index = 0.77) but suboptimal calibration, with improved MFS for intermediate- and high-risk patients (5-year MFS 85% and 50%, respectively) compared to the original Leibovich cohort (74% and 31%) and a historic (1998-2006) UK cohort (76% and 37%). The proportion of variation in outcome explained by the model is low and has declined over time (28% historic vs 22% contemporary UK cohort). CONCLUSION: Prognostic models are widely employed in patients with localized RCC to guide surveillance intensity and clinical trial selection. However, the majority of the variation in outcome remains unexplained by the Leibovich model and, over time, MFS rates among intermediate- and high-risk classified patients have altered. These findings are likely to have implications for all such models used in this setting.
引用
- Vasudev NS, Hutchinson M, Trainor S, et al. UK Multicenter Prospective Evaluation of the Leibovich Score in Localized Renal Cell Carcinoma: Performance has Altered Over Time. Urology. 2019. PMID: 31705948. doi:10.1016/j.urology.2019.09.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。